Is this your business? Claim it to manage your IP and profile
The xT CDx is a sophisticated genomic profiling platform designed to enhance personalized therapeutic opportunities for cancer patients. It integrates extensive molecular profiling with clinical data, optimizing targeted therapies and identifying potential clinical trials. This platform is superior in its ability to conduct paired tumor and normal sequencing, augmented by transcriptome sequencing, which surpasses tumor-only DNA panel tests in accuracy and comprehensiveness. With its robust capabilities, the xT CDx enables the identification of actionable genetic variants that might be overlooked if only traditional solid tumor or liquid biopsy testing methods were employed. This comprehensive approach allows clinicians to make more informed treatment decisions, offering patients tailored therapeutic options and improving their clinical outcomes. The system’s compatibility with various clinical settings is further underscored by its ease of integration into existing workflows, making it a versatile tool for medical professionals aiming to implement precision medicine in oncology practice efficiently.
The xF+ Liquid Biopsy Panel represents a cutting-edge approach in non-invasive cancer diagnostics, utilizing circulating tumor DNA (ctDNA) to provide a snapshot of tumor genomics from a simple blood sample. This innovative panel is designed to detect a comprehensive range of genomic alterations across various cancer types, offering valuable insights into tumor dynamics and aiding in the personalization of treatment strategies. By enabling the monitoring of tumor evolution and treatment response over time, the xF+ Liquid Biopsy Panel supports oncology care by providing real-time genomic data that informs decision-making. This approach is particularly advantageous for patients where traditional biopsy is not feasible, ensuring continuity of care through less invasive means. The panel's integration into the clinical workflow is streamlined, designed to complement traditional tissue biopsy results, or stand-alone as a primary diagnostic tool in selecting and adjusting therapeutic courses. Its high sensitivity and specificity make it a potent tool for tracking disease progression and therapeutic efficacy, reinforcing the shift towards more personalized cancer management.
The DPYD Test is an essential tool in the realm of precision medicine, primarily for oncology applications, where it helps identify patients at risk of serious toxicity when treated with fluoropyrimidine-based chemotherapy. This pharmacogenomic test screens for variants in the DPYD gene known to impair drug metabolism, thus helping prevent adverse reactions. By employing the DPYD Test, healthcare providers can personalize cancer treatment regimens, ensuring that fluoropyrimidine therapy is administered safely or modified based on the genetic profile of the patient. This approach not only improves clinical outcomes by optimizing treatment effectiveness but also aligns with personalized medicine's goal to minimize potential drug-related harm. Integration of the DPYD Test results into clinical care pathways facilitates a tailored therapeutic approach, leveraging genetic insights to guide dose adjustments or alternative drug choices. Its rapid and comprehensive analysis supports oncologists in making informed decisions regarding patient management, ultimately enhancing the quality of care.
Tempus xT CDx offers a comprehensive molecular analysis platform that is revolutionizing cancer care by providing detailed genomic data critical for targeted treatment decisions. This platform merges genomic sequencing with clinical data insights, significantly enhancing the ability to match patients with appropriate therapies and relevant clinical trials. Its unique methodology involves paired sequencing of tumor and non-tumor samples, bolstered by transcriptome analysis, which improves the accuracy of genetic variation detection beyond what stand-alone DNA tests can achieve. The platform is particularly valuable in identifying previously undetected mutations and providing essential information for precision oncology. With its advanced capabilities, Tempus xT CDx aids oncologists in customizing treatment plans, thereby maximizing the potential efficacy of interventions and minimizing unnecessary toxicity for patients. Adaptable to various healthcare settings, the platform integrates seamlessly into existing digital infrastructures, ensuring that genetic insights are quickly and efficiently leveraged to improve patient management strategies. By continuously updating its algorithmic models with real-world data, Tempus xT CDx remains at the forefront of personalized cancer medicine.
Intel expands its foundry ecosystem with alliances with TSMC, UMC, and Taiwanese tech partners, marking a major transformation for the firm's production strategy. Read more
Join the world's most advanced semiconductor IP marketplace!
It's free, and you'll get all the tools you need to discover IP, meet vendors and manage your IP workflow!
No credit card or payment details required.
Join the world's most advanced AI-powered semiconductor IP marketplace!
It's free, and you'll get all the tools you need to advertise and discover semiconductor IP, keep up-to-date with the latest semiconductor news and more!
Plus we'll send you our free weekly report on the semiconductor industry and the latest IP launches!
To evaluate IP you need to be logged into a buyer profile. Select a profile below, or create a new buyer profile for your company.
